Expression of FGFR3 during human testis development and in germ cell-derived tumours of young adults

International Journal of Developmental Biology

Volumn 57, Issue 2-4, 2013, Pages 141-151

  Ewen, Katherine A ^a   Olesen, Inge A ^a   Winge, Sofia B ^a   Nielsen, Ana R ^a   Nielsen, John E ^a   Graem, Niels ^a   Juul, Anders ^a   Rajpert De Meyts, Ewa ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Carcinoma in situ; FGFR3; Germ cell; Testicular neoplasm; Testis

Indexed keywords

CYCLINE; FIBROBLAST GROWTH FACTOR RECEPTOR 3; ISOPROTEIN; KI 67 ANTIGEN; PHOSPHOPROTEIN; RECEPTOR SUBTYPE;

ADULT; ARTICLE; CANCER STEM CELL; CARCINOGENESIS; CARCINOMA IN SITU; CELL MEMBRANE; CELL PROLIFERATION; CELL SURVIVAL; CLINICAL ARTICLE; CLINICAL OBSERVATION; CONTROLLED STUDY; CYTOPLASM; DEVELOPMENT; EMBRYONAL CARCINOMA; FETUS; GENE MUTATION; GERM CELL; GERM CELL TUMOR; GESTATIONAL AGE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INFANCY; MALE; ONTOGENY; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PUBERTY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SEMINOMA; SIGNAL TRANSDUCTION; SPERMATOGENESIS; SPERMATOGONIUM; TESTIS DEVELOPMENT; WESTERN BLOTTING;

ADOLESCENT; ADULT; BLOTTING, WESTERN; CARCINOMA IN SITU; CELL DIFFERENTIATION; CELL PROLIFERATION; CHILD; CHILD, PRESCHOOL; FETUS; GENE EXPRESSION REGULATION, DEVELOPMENTAL; HUMANS; IMMUNOENZYME TECHNIQUES; INFANT; INFANT, NEWBORN; KI-67 ANTIGEN; MALE; NEOPLASMS, GERM CELL AND EMBRYONAL; PHOSPHORYLATION; PROLIFERATING CELL NUCLEAR ANTIGEN; REAL-TIME POLYMERASE CHAIN REACTION; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 3; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TESTICULAR NEOPLASMS; TESTIS; YOUNG ADULT;

EID: 84880063360     PISSN: 02146282     EISSN: None     Source Type: Journal    
DOI: 10.1387/ijdb.130022er     Document Type: Article

References (63)

1. AKSGLÆDE L, WIKSTRÖM AM, RAJPERT-DE MEYTS E, DUNKEL L, SKAKKE-BÆK NE, JUUL A (2006). Natural history of seminiferous tubule degeneration in Klinefelter syndrome. Hum Reprod Update 12: 39-48.
2. AUBRY F, SATIE A-P, RIOUX-LECLERCQ N, RAJPERT-DE MEYTS E, SPAGNOLI GC, CHOMEZ P, DE BACKER O, JEGOU B, SAMSON M (2001). MAGE-A4, a germ-cell specific marker is differentially expressed in testicular tumours. Cancer 902: 2778-2785.
3. BERENSZTEIN EB, SCIARA MI, RIVAROLA MA, BELGOROSKY A (2002). Apoptosis and proliferation of human testicular somatic and germ cells during prepuberty: High rate of testicular growth in newborns mediated by decreased apoptosis. J Clin Endocrinol Metab 87:5113-5118.
4. BIGNELL G, SMITH R, HUNTER C, STEPHENS P, DAVIES H, GREENMAN C, TEAGUE J, BUTLER A, EDKINS S, STEVENS C et al. (2006). Sequence analysis of the protein kinase gene family in human testicular germ-cell tumors of adoles-cents and adults. Genes, Chromosomes Cancer 45: 42-46.
5. BOWLES J, FENG CW, SPILLER C, DAVIDSON TL, JACKSON A, KOOPMAN P (2010). FGF9 suppresses meiosis and promotes male germ cell fate in mice. Dev Cell 19: 440-449.
6. BRYANT DM, STOW JL (2005). Nuclear translocation of cell-surface receptors: Les-sons from fibroblast growth factor. Traffic 6: 947-953.
7. CANCILLA B, DAVIES A, FORD-PERRISS M, RISBRIDGER GP (2000). Discrete cell-and stage-specific localisation of fibroblast growth factors and receptor expression during testis development. J Endocrinol 164: 149-159.
8. CANCILLA B, RISBRIDGER GP (1998). Differential localization of fibroblast growth factor receptor-1, -2, -3, and-4 in fetal, immature, and adult rat testes. Biol Reprod 58:1138-1145.
9. CAPPELLEN D, DE OLIVEIRA C, RICOL D, DE MEDINA S, BOURDIN J, SASTRE-GARAU X, CHOPIN D, THIERY JP, RADVANYI F. (1999). Frequent activating mutations of FGFR3 in human bladder and cervix carcinomas. Nat Genet 23: 18-20.
10. CHESI M, NARDINI E, BRENTS LA, SCHROCK E, RIED T, KUEHL WM, BERGSA-GEL PL. (1997) Frequent translocation t(4;14)(p16.3;q32.3) in multiple myeloma is associated with increased expression and activating mutations of fibroblast growth factor receptor 3. Nat Genet 16: 260-264.
11. DEGNIN CR, LAEDERICH MB, HORTON WA (2011). Ligand activation leads to regulated intramembrane proteolysis of fibroblast growth factor receptor 3. Mol Biol Cell. 22:3861-3873.
12. DURCOVA-HILLS G, ADAMS IR, BARTON SC, SURANI MA, MCLAREN A (2006). The role of exogenous fibroblast growth factor-2 on the reprogramming of primordial germ cells into pluripotent stem cells. Stem Cells 24: 1441-1449.
13. EBLE JN (1994). Spermatocytic seminoma. Hum Pathol 25: 1035-1042.
14. GASKELL TL, ESNAL A, ROBINSON LL, ANDERSON RA, SAUNDERS PT (2004) Immunohistochemical profiling of germ cells within the human fetal testis: identi-fication of three subpopulations. Biol Reprod 71: 2012-2021.
15. GORIELY A, HANSEN RMS, TAYLOR IB, OLESEN IA, JACOBSEN GK, MCGOWAN SJ, PFEIFER SP, MCVEAN GAT, RAJPERT-DE MEYTS E, WILKIE AOM (2009). Activating mutations in FGFR3 and HRAS reveal a shared genetic origin for congenital disorders and testicular tumors. Nat Genet 41: 1247-1252.
16. GORIELY A, WILKIE AO (2012). Paternal age effect mutations and selfish sper-matogonial selection: causes and consequences for human disease. Am J Hum Genet 10: 175-200.
17. GREENMAN C, STEPHENS P, SMITH R, DALGLIESH GL, HUNTER C, BIGNELL G, DAVIES H, TEAGUE J, BUTLER A, STEVENS C et al. (2007). Patterns of somatic mutation in human cancer genomes. Nature 446:153-158.
18. GUELER B, SONNE SB, ZIMMER J, HILSCHER B, HILSCHER W, GRAEM N, RAJPERT-DE MEYTS E, VOGT PH (2012). AZFa protein DDX3Y is differentially expressed in male germ cells during development and in testicular tumours: new evidence for phenotypic plasticity of germ cells. Hum Reprod; 27: 1547-1555.
19. HANSEN RMS, GORIELY A, WALL SA, ROBERTS ISD, WILKIE AOM (2005). Fibro-blast growth factor receptor 2, gain-of-function mutations, and tumourigenesis: investigating a potential link. J Pathol 207: 27-31.
20. HARADA D, YAMANAKA Y, UEDA K, TANAKA H, SEINO Y (2009). FGFR3-related dwarfism and cell signaling. J Bone Miner Metab 27: 9-15.
21. HONECKER F, STOOP H, DE KRIJGER RR, LAU YFC, BOKEMEYER C, LOOIJENGA LHJ. (2004) Pathobiological implications of the expression of markers of testicular carcinoma in situ by fetal germ cells. J Pathol 203:849-857.
22. JOHNSON DE, LU J, CHEN H, WERNER S, WILLIAMS LT (1991). The human fibro-blast growth factor receptor genes: a common structural arrangement underlies the mechanisms for generating receptor forms that differ in their third immunoglobulin domain. Mol Cell Biol 11: 4627-4634.
23. JOHNSON DE, WILLIAMS LT (1992). Structural and functional diversity in the FGF receptor multigene family. Adv Cancer Res 60: 1-41.
24. JØRGENSEN N, GIWERCMAN A, MÜLLER J, SKAKKEBÆK NE (1993). Immuno-histochemical markers of carcinoma in situ of the testis also expressed in normal infantile germ cells. Histopathology 22: 373-378.
25. JØRGENSEN N, RAJPERT-DE MEYTS E, GRÆM N, MÜLLER J, GIWERCMAN A, SKAKKEBÆK NE (1995). Expression of immunohistochemical markers for tes-ticular carcinoma in situ by normal human fetal germ cells. Lab Invest 72: 223-231.
26. JUUL A, AKSGLÆDE L, LUND AM, DUNO M, SKAKKEBÆK NE, RAJPERT-DE MEYTS E (2007). Preserved fertility in a non-mosaic Klinefelter patient with a mutation in the fibroblast growth factor receptor 3 gene: Case Report. Hum Reprod 22: 1907-1911.
27. KETOLA I, TOPPARI J, VASKIVUO T, HERVA R, TAPANAINEN JS, HEIKINHEIMO M (2003). Transcription factor GATA-6, cell proliferation, apoptosis, and apoptosis-related proteins Bcl-2 and Bax in human fetal testis. J Clin Endocrinol Metab 88: 1858-1865.
28. KULAKOVA TA, IGNAT'EV I (1986) Achondroplasia associated with Klinefelter's syndrome. Klinicheskaia meditsina 64: 126-128.
29. LANGE M, THULESEN J, FELDT-RASMUSSEN U, SKAKKEBÆK NE, VAHL N, JØRGENSEN JO, CHRISTIANSEN JS, POULSEN SS, SNEPPEN SB, JUUL A (2001). Skin morphological changes in growth hormone deficiency and acromegaly. Eur J Endocrinol 145: 147-153.
30. LEE PL, JOHNSON DE, COUSENS LS, FRIED VA, WILLIAMS LT (1989). Purifica-tion and complementary DNA cloning of a receptor for basic fibroblast growth factor. Science 245: 57-60.
31. LIM J, GORIELY A, TURNER GD, EWEN KA, JACOBSEN GK, GRAEM N, WILKIE AO, RAJPERT-DE MEYTS E (2011). OCT2, SSX and SAGE1 reveal the pheno-typic heterogeneity of spermatocytic seminoma reflecting distinct subpopulations of spermatogonia. J Pathol 224: 473-83.
32. LOOIJENGA LH, STOOP H, HERSMUS R, GILLIS AJ, OOSTERHUIS JW (2007). Genomic and expression profiling of human spermatocytic seminomas: patho-genetic implications. Int J Androl 30: 328-335.
33. MOHAMMADI M, DIKIC I, SOROKIN A, BURGESS WH, JAYE M, SCHLESSINGER J (1996). Identification of six novel autophosphorylation sites on fibroblast growth factor receptor 1 and elucidation of their importance in receptor activation and signal transduction. Mol Cell Biol 16: 977-989.
34. MÜLLER J, SKAKKEBÆK NE (1983). Quantification of germ cells and seminiferous tubules by stereological examination of testicles from 50 boys who suffered from sudden death. Int J Androl 6:143-156.
35. NIELSEN JE, HANSEN MA, JØRGENSEN M, TANAKA M, ALMSTRUP K, SKAK-KEBÆK NE, LEFFERS H (2003). Germ cell differentiation-dependent and stage-specific expression of LANCL1 in rodent testis. Eur J Histochem 47: 215-222.
36. OR-RURTREGER A, BEDFORD MT, BURAKOVA T, ARMAN E, ZIMMER Y, YAYON A, GIVOL D, LONAI P (1993). Developmental localization of the splicing alternatives of fibroblast growth factor receptor-2 (FGFR2). Dev Biol 158: 475-486.
37. PANIAGUA R, NISTAL M (1984) Morphological and histometric study of human spermatogonia from birth to the onset of puberty. J Anat 139: 535-552.
38. PENROSE LS (1957). Parental age in achondroplasia and mongolism. Am J Hum Genet 9: 167-169.
39. RAJPERT-DE MEYTS E, KVIST M, SKAKKEBÆK NE (1996). Heterogeneity of ex-pression of immunohistochemical tumour markers in the testicular carcinoma-in situ: Pathogenetic relevance. Virchows Arch 428: 133-139.
40. RAJPERT-DE MEYTS E, JØRGENSEN N, GRÆM N, MÜLLER J, CATE RL, SKAK-KEBÆK NE (1999) Expression of anti-Müllerian hormone during normal and pathological gonadal development: Association with differentiation of Sertoli and granulosa cells. J Clin Endocrinol Metab 84: 3836-3844.
41. RAJPERT-DE MEYTS E, JACOBSEN GK, BARTKOVA J, AUBRY F, SAMSON M, BARTEK J, SKAKKEBÆK NE (2003). The immunohistochemical expression pattern of Chk2, p53, p19INK4d, MAGE-A4 and other selected antigens provides new evidence for the premeiotic origin of spermatocytic seminoma. Histopathol-ogy 42: 217-226.
42. RAJPERT-DE MEYTS E, HANSTEIN R, JØRGENSEN N, GRÆM N, VOGT PH, SKAKKEBÆK NE (2004) Developmental expression of the POU5F1 (OCT-3/4) in normal and dysgenetic human gonads. Hum Reprod 19: 1338-1344.
43. REY, R., AL-ATTAR L, LOUIS F, JAUBERT F, BARBET P, NIHOUL-FEKETE C, CHAUSSAIN JL, JOSSO N (1996). Testicular dysgenesis does not affect expres-sion of anti-mullerian hormone by Sertoli cells in premeiotic seminiferous tubules. Am J Pathol 148: 1689-1698.
44. RICHELDA R, RONCHETTI D, BALDINI L, CRO L, VIGGIANO L, MARZELLA R, ROCCHI M, OTSUKI T, LOMBARDI L, MAIOLO AT, NERI A (1997). A novel chromosomal translocation t(4; 14)(p16.3; q32) in multiple myeloma involves the fibroblast growth-factor receptor 3 gene. Blood 90: 4062-4070.
45. ROBIN NH, FALK MJ, HALDEMAN-ENGLERT CR (1998; updated 2011). FGFR-Related Craniosynostosis Syndromes. In: Pagon RA, Bird TD, Dolan CR, Stephens K, Adam MP, editors. GeneReviews™ [Internet]. Seattle (WA): University of Wash-ington, Seattle; 1993-. Available from http://www.ncbi.nlm.nih.gov/books/NBK1455/
46. SAYLI BS, GÜL D, CAKIRBAY H (1994). Achondroplasia with XXY karyotype. Clin Genet 45: 217-218.
47. SCHMAHL J, KIM Y, COLVIN JS, ORNITZ DM, CAPEL B (2004). Fgf9 induces proliferation and nuclear localization of FGFR2 in Sertoli precursors during male sex determination. Development 131: 3627-3636.
48. SENDRAIL M, GLEIZES L, SENDRAIL-PESQUÉ M, COLOMBIÉS P (1967). Kline-felter's polygonosomy and achondroplasia. Sem Hop 43: 1217-1225.
49. SKAKKEBÆK NE (1972). Possible carcinoma-in-situ of the testis. Lancet 2: 516-517.
50. SKAKKEBÆK NE, BERTHELSEN JG, GIWERCMAN A, MÜLLER J (1987). Carcinoma-in-situ of the testis: possible origin from gonocytes and precursor of all types of germ cell tumours except spermatocytoma. Int J Androl 10, 19-28.
51. SONNE SB, ALMSTRUP K, DALGAARD M, JUNCKER AS, EDSGARD D, RUBAN L, HARRISON NJ, SCHWAGER C, ABDOLLAHI A, HUBER PE, BRUNAK S, GJERDRUM LM, MOORE HD, ANDREWS PW, SKAKKEBAEK NE, RAJPERT-DE MEYTS E, LEFFERS H (2009). Analysis of gene expression profiles of microdis-sected cell populations indicates that testicular carcinoma in situ is an arrested gonocyte. Cancer Res 69: 5241-5250.
52. SONNE SB, HOEI-HANSEN CE, NIELSEN JE, HERLIHY AS, ANDERSSON AM, ALMSTRUP K, DAUGAARD G, SKAKKEBÆK NE, LEFFERS H, RAJPERT-DE MEYTS E (2006). CDH1 (E-cadherin) in testicular germ cell neoplasia: Suppressed translation of mRNA in pre-invasive carcinoma in situ but increased protein levels in advanced tumours. APMIS 114: 549-558.
53. STEGER K, TETENS F, SEITZ J, GROTHE C, BERGMANN M (1998). Localization of fibroblast growth factor 2 (FGF-2) protein and the receptors FGFR 1-4 in normal human seminiferous epithelium. Histochem Cell Biol 110: 57-62.
54. STOIMENOV I, HELLEDAY T (2009). PCNA on the crossroad of cancer. Biochem Soc Trans 37: 605-613.
55. TAKEUCHI Y, MOLYNEAUX K, RUNYAN C, SCHAIBLE K, WYLIE C (2005). The roles of FGF signaling in germ cell migration in the mouse. Development 132: 5399-5409.
56. VAN RHIJN BWG, VAN TILBORG AAG, LURKIN I, BONAVENTURE J, DE VRIES A, THIERY JP, VAN DER KWAST TH, ZWARTHOFF EC, RADVANYI F (2002). Novel fibroblast growth factor receptor 3 (FGFR3) mutations in bladder cancer previously identified in non-lethal skeletal disorders. Eur J Hum Genet 10: 819-824.
57. VON KOPYLOW K, KIRCHHOFF C, JEZEK D, SCHULZE W, FEIG C, PRIMIG M, STEINKRAUS V, SPIESS AN (2010). Screening for biomarkers of spermatogonia within the human testis: a whole genome approach. Hum Reprod 25: 1104-1112.
58. VON KOPYLOW K, STAEGE H, SPIESS AN, SCHULZE W, WILL H, PRIMIG M, KIRCHHOFF C (2012a). Differential marker protein expression specifies rarefac-tion zone-containing human Adark spermatogonia. Reproduction. 143: 45-57.
59. VON KOPYLOW K, STAEGE H, SCHULZE W, WILL H, KIRCHHOFF C (2012b). Fibroblast growth factor receptor 3 is highly expressed in rarely dividing human type A spermatogonia. Histochem Cell Biol. 138: 759-772.
60. WELLS A, MARTI U (2002). Signalling shortcuts: Cell-surface receptors in the nucleus? Nat Rev Mol Cell Biol 3: 697-702.
61. WILKIE AO (2005) Bad bones, absent smell, selfish testes: the pleiotropic consequences of human FGF receptor mutations. Cytokine Growth Factor Rev. 16: 187-203.
62. WILKIN DJ, SZABO JK, CAMERON R, HENDERSON S, BELLUS GA, MACK ML, KAITILA I, LOUGHLIN J, MUNNICH A, SYKES B, BONAVENTURE J, FRAN-COMANO CA (1998). Mutations in fibroblast growth-factor receptor 3 in sporadic cases of achondroplasia occur exclusively on the paternally derived chromosome. Am J Hum Genet 63: 711-716.
63. WILLERTON L, SMITH RA, RUSSELL D, MACKAY S (2004). Effects of FGF9 on embryonic Sertoli cell proliferation and testicular cord formation in the mouse. Int J Dev Biol 48: 637-643.